Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16246797 | 0.86 | KLKB1 (0.54) | KLKB1 | |
| SCHEMBL16246824 | 0.84 | KLKB1 (0.59) | KLKB1HSD17B10 | |
| SCHEMBL16247180 | 0.83 | KLKB1 (0.53) | KLKB1HSD17B10 | |
| SCHEMBL28228565 | 0.81 | KLKB1 (0.52) | KLKB1HSD17B10 | |
| SCHEMBL16246898 | 0.81 | KLKB1 (0.57) | KLKB1 | |
| SCHEMBL16246944 | 0.81 | KLKB1 (0.55) | KLKB1 | |
| SCHEMBL17786778 | 0.81 | KLKB1 (0.47) | KLKB1 | |
| SCHEMBL16246939 | 0.80 | KLKB1 (0.58) | KLKB1HSD17B10 | |
| SCHEMBL16247001 | 0.79 | KLKB1 (0.72) | KLKB1 | |
| SCHEMBL16246727 | 0.79 | KLKB1 (0.59) | KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105452240-B | Hete rocyclic derivatives | 卡尔维斯塔制药有限公司 | 2018-06-26 | — | — | CN | claimed |
| EP-3305778-A1 | INHIBITORS OF PLASMA KALLIKREIN | Kalvista Pharmaceuticals Limited (GB) | 2018-04-11 | — | — | EP | claimed |
| EP-2999697-B1 | HETEROCYCLIC DERIVATES | KALVISTA PHARMACEUTICALS LTD (GB) | 2017-04-19 | — | — | EP | claimed |
| US-9533987-B2 | Heterocyclic derivates | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2017-01-03 | — | — | US | claimed |
| WO-2016083816-A1 | N-((HETEROARYLMETHYL)-HETEROARYL-CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-06-02 | — | — | WO | claimed |
| US-20160108036-A1 | HETEROCYCLIC DERIVATES | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-04-21 | — | — | US | claimed |
| EP-2999697-A1 | HETEROCYCLIC DERIVATES | Kalvista Pharmaceuticals Limited (GB) | 2016-03-30 | — | — | EP | claimed |
| WO-2014188211-A1 | HETEROCYCLIC DERIVATES | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2014-11-27 | — | — | WO | claimed |
| EP-3305778-B1 | INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2022-01-19 | — | — | EP | disclosed |
| CN-105452240-B | Hete rocyclic derivatives | 卡尔维斯塔制药有限公司 | 2018-06-26 | — | — | CN | disclosed |
| EP-3305778-A1 | INHIBITORS OF PLASMA KALLIKREIN | Kalvista Pharmaceuticals Limited (GB) | 2018-04-11 | — | — | EP | disclosed |
| EP-2999697-B1 | HETEROCYCLIC DERIVATES | KALVISTA PHARMACEUTICALS LTD (GB) | 2017-04-19 | — | — | EP | disclosed |
| US-9533987-B2 | Heterocyclic derivates | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2017-01-03 | — | — | US | disclosed |
| WO-2016083816-A1 | N-((HETEROARYLMETHYL)-HETEROARYL-CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-06-02 | — | — | WO | disclosed |
| US-20160108036-A1 | HETEROCYCLIC DERIVATES | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-04-21 | — | — | US | disclosed |
| EP-2999697-A1 | HETEROCYCLIC DERIVATES | Kalvista Pharmaceuticals Limited (GB) | 2016-03-30 | — | — | EP | disclosed |
| WO-2014188211-A1 | HETEROCYCLIC DERIVATES | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2014-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108036-A1 | HETEROCYCLIC DERIVATES | BDKRB1, KLKB1, BDKRB2 | KLKB1 2/4885HSD17B10 1354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.